## Disclosure of Relevant Financial Relationships with Commercial Companies Spring 2021 SWOG Group Meeting

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved prior to this program.

## A. Financial Disclosures Related to CME Activities and Requirements:

Planner/Faculty Member	Nature of Relationship	Company
Manmeet Ahluwalia	Consultant	Bayer, Novoure, Kiyatec, Insightec, GSK, Soft, Nuvation, Cellularity, Apollomics
	Grant/Research Support (Principal Investigator)	Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novoure, Mimivax, Merck
	Stock Shareholder (Self-managed)	Doctible, Mimivax, Cytodyn
Syed A. Ahmad	Speaker's Bureau	AbbVie
Catherine M. Alfano	No Disclosures	
Alain P Algazi	Consultant	OncoSec Medical, Inc; Valitor Bio
	Grant/Research Support (Principal Investigator)	Array, Acerta, BMS, AstraZeneca, Merck, Incyte, Iovance, Dynavax, Idera, Sensei, Tessa, Ascendis
	Stock Shareholder (Self-managed)	OncoSec Medical, Inc; Valitor Bio
Jennifer Amengual	Consultant	Daiichi Sankyo, Seagen
	Grant/Research Support (Principal Investigator)	Appia Pharmaceuticals
Banu Arun	Grant/Research Support (Principal Investigator)	Research Grant: CPRIT, NCI, Susan Komen Research paid to institution: AbbVie, AstraZeneca, Pharmacia, Invitae
Marie Bakitas	No Disclosures	
Rick Bangs	No Disclosures	
Paul Barr	Consultant	TG therapeutics, BMS, Genentech
Charles Blanke	No Disclosures	
Paolo Bonato	Grant/Research Support (Principal Investigator)	American Heart Association, Department of Defense, Michael J Fox Foundation, NIH, NSF, Peabody Foundation including sub-awards on NIH and NSF SBIR grants from Barrett. Technology, BioSensics, Veristride, Emerge Diagnostics, MC10, Mitsui Chemicals, Pfizer, Shimmer Research, SynPhNe

Paolo Bonato, cont'd	Other	Advisory Board: SwanBio, Michael J Fox Foundation, England Pediatric Device Consortium, Walking Tall-PD clinical trial, Research Australia. Scientific Advisory: ABLE, Human Motion FormSense, Hocoma AG, Trexo
Elizabeth Brem	Consultant	TG Therapeutics
	Speaker's Bureau	SeaGen, Incyte, BeiGene, Pharmacyclics
	Other	Advisory Boards: Karyopharm, Morphosys, Bayer
Lauren Byers	Consultant	AstraZeneca, GenMab, Sierra Oncology, Bristol-Myers Squibb, Alethia, Merck, Pfizer, PharmaMar, AbbVie, Jazz Pharmaceuticals
	Grant/Research Support (Principal Investigator)	AstraZeneca, Genmab, Sierra Oncology, Tolero Pharmaceuticals
Allison Caban-Holt	No Disclosures	
Young Kwang Chae	Consultant	Bristol Myers-Squibb, Biodesix, Tempus, Foundation Medicine
	Speaker's Bureau	Bristol Meyers-Squibb, AstraZeneca, Genentech, Lilly Oncology
	Grant/Research Support (Principal Investigator)	Bristol Myers-Squibb, Biodesix, Lexent Bio, Freenome
Helen Chen	No Disclosures	
Vincent Chung	Consultant	Pfizer, Perthera, RenovoRX
	Speaker's Bureau	Ipsen, Coherus, Astra Zeneca
	Grant/Research Support (Principal Investigator)	Merck
Benjamin Corn	No Disclosures	
Morgan Cox	No Disclosures	
Michael D'Angelica	No Disclosures	
Lara Davis	No Disclosures	
Roy Decker	Consultant	AstraZeneca
	Speaker's Bureau	AstraZeneca
Tiffin Despres	Stock Shareholder (Self-managed)	Celgene/BMS
Don Dizon	Consultant	AstraZeneca, Merck, Clovis, Regeneron
	Research Grant	BMS, Kazai, Tesaro, Pfizer
Lee Ellis	Consultant	Oncohost LTD
	Other: (must specify)	Fibrogen (Data Monitoring Committee), New Beta Innovation (Data Monitoring Committee)
Harry Erba	Consultant	AbbVie, Agios, ALX Oncology, Astellas, Celgene/BMS, Daiichi Sankyo, Genentech, GlycoMinetics, Incyte, Jazz, Kura Oncology, Novartis, Takeda, Trillium
	Speaker's Bureau	AbbVie, Agios, Celgene/BMS, Incyte, Jazz, Novartis

	T	
Harry Erba, cont'd	Grant/Research Support (Principal Investigator)	AbbVie, Agios, ALX Oncology, Amgen, Daiichi Sankyo, Forma, Forty-Seven, Gilead, GlycoMinetics, ImmunoGen, Jazz Macrogenics, Novartis, PTC
	Other	Chair IRC: Covance/AbbVie; Chair of AML Registry Steering Cmte: Celgene
David B. Feldman	No Disclosures	
Jonathan Friedberg	Consultant	DSMC: Bayer and Ascerta
	Other	Patent Royalties (spouse)
Sepideh Gholami	No Disclosures	
Saar Gill	Stock Shareholder (Self-managed)	Carisma Therapeutics
Kenneth Grossmann	Consultant	Array BioPharma, BMS, Novartis
Samantha Guild	No Disclosures	
Krishna Gunturu	No Disclosures	
Patrick A Hagen	Speaker's Bureau	Sanofi
Balazs Halmos	Consultant	Merck, Pfizer, Genentech, AstraZeneca, TPT, Apollomics, Novartis, Boehringer-Ingelheim
	Grant/Research Support (Principal Investigator)	Mirati, AbbVie, AstraZeneca, Merck, BMS, Eli-Lilly, Novartis Pfizer, Amgen, Advaxis, Blueprint, Elevation, GSK
Andrea Harzstark	No Disclosures	
Daniel Hayes	No Disclosures	
Norah Lynn Henry	No Disclosures	
Alex Herrera	Consultant	BMS, Merck, Genentech, Inc./F. Hoffmann-La Roche Ltd, Seattle Genetics, Karyopharm, Takeda, Tubulis, AstraZeneca
	Grant/Research Support (Principal Investigator)	BMS, Merck, Genentech, Inc./F. Hoffmann-La Roche Ltd, Gilead Sciences, Seattle Genetics, AstraZeneca, ADC Therapeutics
Dawn Hershman	No Disclosures	
Brian Hess	Consultant	ADC Therapeutics
	Speaker's Bureau	BMS, AstraZeneca,
Brian Hill	Consultant	Genentech, Abbvie
	Grant/Research Support (Principal Investigator)	Genentech, Abbvie
Randall Holcombe	Other	Chair, Data and Safety Monitoring Committee for MERCK for a colon cancer clinical trial. No relationship to topic of presentation.
Johanna Horn	No Disclosures	
David P. Horowitz	No Disclosures	
Nasheed Hossain	No Disclosures	

Siwen Hu-Lieskovan	Consultant	BMS, Amgen, Xencor, Genmab, Regeneron
Melinda Irwin	No Disclosures	
Tanner Johanns	No Disclosures	
Rebecca Johnson	Consultant	Servier Pharmaceuticals (occasional ad hoc consultant)
	Speaker's Bureau	Servier Pharmaceuticals
	Grant/Research Support (Principal Investigator)	PCORI Engagement award #20242 (2021)-"Video conferences to share strategies on building Adolescent and Young Adult (AYA) oncology councils"
Lisa Kachnic	No Disclosures	
Karen Kelly	Advisory Board	AbbVie, Amgen, AstraZeneca, Daiichi Sanko, DebioPharm EMD Serono, GenMab, Genentech, Lilly, Novartis, Regeneron, Takeda
	Research Grant	AbbVie, Amgen, Astellas, EMD Serono, Genentech, Novartis, Regeneron, Tizona
	Other	iDMC- AstraZeneca: Author Royalties – Up to Date
Kari Kendra	No Disclosures	
Amrita Krishnan	Consultant	Janssen, BMS, Regeneron, GSK
	Speaker's Bureau	BMS, Takeda, Amgen, GSK
	Grant/Research Support (Principal Investigator)	Janssen
	Stock Shareholder (Self-managed)	BMS
Robert Krouse	No Disclosures	
Razelle Kurzrock	Consultant	X-Biotech, Neomed, Pfizer, Actuate Therapeutics, Roche, Turnin Therapeutics, TD2/Volastra, Bicara Therapeutics, Inc.
	Speaker's Bureau	Roche
	Grant/Research Support (Principal Investigator)	Genentech, Merck Serono, Pfizer, Boehringer Ingelheim, TopAlliance, Takeda, Incyte, Debiopharm, Medimmune, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Omniseq, and Guardant
	Stock Shareholder (Self-managed)	IdbyDNA, CureMatch, Inc. (start-up)
	Other	Board Member: CureMatch, Inc. (start-up), CureMetrix, Inc. (start-co-Founder: CureMatch, Inc.(start-up)
David Lawson	No Disclosures	
Scott M. Lippman	No Disclosures	
Edison Liu	No Disclosures	
Jason Luke	Consultant	7 Hills, Fstar, RefleXion, Abbvie, Alnylam, Array, Bayer, Bristol-Myers Squibb, Checkmate, Cstone, Eisai, EMD Serono, Flame

Jason Luke, cont'd	Grant/Research Support (Principal Investigator)	AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb (IIT & industry), Corvus, EMD Serono, Genmab, Ikena, Immatics, In
	Stock Shareholder (Self-managed)	Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.Al, Pyxis, Tempest
Joshua Mammen	No Disclosures	
Richard Maziarz	Consultant	Novartis, Incyte
	Grant/Research Support (Principal Investigator)	Novartis, Incyte
	Other	Novartis, DSMB Membership (2 clinical trials)
Monica Mita	No Disclosures	
Halle Moore	Grant/Research Support (Principal Investigator)	AbbVie, Daiichi-Sankyo, AstraZeneca, Roche/Genentech (all to institution)
Lucia Nappi	No Disclosures	
Marian Neuhouser	No Disclosures	
Izumi Okado	No Disclosures	
Robert Orlowski	Advisory Board	Amgen, Bristol-Myers Squibb, Janssen Biotech, Karyopharm Therapeutics, Oncopeptides AB, Regeneron Pharmaceuticals, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc.
	Grant/Research Support (Principal Investigator)	Clinical: CARsgen Therapeutics, Celgene, Exelixis, Janssen Biote Sanofi-Aventis, Takeda Pharmaceuticals North America, Lab: BioTheryX.
Mark O'Rourke	No Disclosures	
Ko Un "Clara" Park	No Disclosures	
Susan Parsons	Consultant	Seattle Genetics
Sandip Patel	Consultant	BMS, Amgen, AstraZeneca, Beigene, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, Rakuten, Tempus
	Grant/Research Support (Principal Investigator)	BMS, Amgen, AstraZeneca/MedImmune, Eli Lilly, Fate Therapeutics, Genocea, Iovance, Merck, Pfizer, Roche/Genentec
Philip Philip	Consultant	Daiichi Sankyo, Novartis, Rafeal Pharmaceuticals, IQVIA Biotech, Merck, Syncore, Trisalus
	Speaker's Bureau	Bayer, Incyte, Novartis
	Grant/Research Support (Principal Investigator)	Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Corcept Therapeutics, Daiichi Sankyo, Eisai, Gritstone, Incyte, IQVIA Biotech, Merck, Natera, NGM Biopharmaceuticals, Novocure, QED Therapeutics, Syncore, Taiho Oncology, Thyme, Trisalus
	Other	DSMB: Blueprint Medicines/Committee, DSMB: Erytech Pharma, Advisory Committee: Caris Diagnostics, Advisory Committee: Daiichi Sankyo, Advisory Committee: Ipsen Biopharmaceuticals, Advisory Committee: Merck, Advisory

		Committee: Novartis, Advisory Committee: Rafeal Pharmaceuticals.
Andrew Poklepovich	Consultant	Novartis, signatera
	Speaker's Bureau	Bristol Myers Squibb
David Polsky	Grant/Research Support (Principal Investigator)	Novartis, Bio-Rad Laboratories
Lajos Pusztai	Consultant	Seagen, Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, and Daiichi
	Grant/Research Support (Principal Investigator)	Susan Komen Foundation, Breast Cancer Research Foundation, NCI, Merck, AstraZeneca, Seagen, Pfizer, Bristol Myers Squibb
Nilsa Ramirez	No Disclosures	
Scott Ramsey	Consultant	BMS, Merck, GRAIL, Pfizer
	Research Grant	FlatIron Health, BMS, Genentech
	Other	Steering Cmte – AstraZeneca, Pfizer; Ad Board – Bayer; Pharmacy & Therapeutics Cmte for – Premera Blue Cross and Regence Blue Shield
Antoni Ribas	Consultant	Amgen, Apexigen, AstraZeneca, Merck, Novartis, Sanofi, Vedanta
	Grant/Research Support (Principal Investigator)	Agilent, Bristol-Myers Squibb
	Stockholder (self-managed)	Advaxis, CytomX, Five Prime, RAPT, Isoplexis, Kite-Gilead 4C Biomed, Apricity, Arcus, Highlight, Compugen, ImaginAb, MapKur
Flavio Rocha	No Disclosures	
Matthew Rock	No Disclosures	
Mazyar Shadman	Consultant	Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squib, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Atara Biotherapeutics
	Grant/Research Support (Principal Investigator)	Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, Atara Biotherapeutics
Heloisa Soares	Consultant	Ipsen, AAA, TerSera, QED therapeutics, Exelixis (all less than 5K within a 12-month period)
Stephen Spurgeon	Grant/Research Support (Principal Investigator)	Acerta Pharma, Genentech
Deborah Stephens	Consultant	Karyopharm, Innate, Beigene, Epizyme, TG Therapeutics, Adaptive
	Grant/Research Support (Principal Investigator)	Karyopharm, Arqule, Acerta, Mingsight, Novartis, Verastem

Patrick Stiff	Grant/Research Support (Principal Investigator)	Leukemia Research Foundation, Peritt Foundation
	Other	DSMB: CRISPR
Hussein A. Tawbi	Consultant	BMS, Merck, Novartis, Genentech, Eisai, Iovance
	Grant/Research Support (Principal Investigator)	BMS, Merck, Novartis, Genentech, GSK, Celgene
Ian Thompson	Consultant	Partners/Harvard University, Profound Medical
	Grant/Research Support (Principal Investigator)	MagForce
Thach-Giao Truong	No Disclosures	
David Tuveson	Consultant	Surface Oncology, Leap Therapeutics, Cygnal Therapeutics, Mestag Therapeutics
	Grant/Research Support (Principal Investigator)	ONO, Mestag, Fibrogen
	Stockholder	Surface Oncology, Leap Therapeutics
	(self-managed)	Scientific co-founder of Mestag therapeutics
	Other	
Anusha Vallurupalli	No Disclosures	Adaptimmune, Deciphera
	Grant/Research Support (Principal Investigator)	Research support to institution: Adaptimmune, Deciphera, Athenex, Incyte, GSK
Christine Veenstra	No Disclosures	
Michael J. Wagner	Consultant	
Courtney Wille	No Disclosures	
William Allen Wood, Jr.	No Disclosures	

## B. Financial Disclosures Related to Scientific Activities of SWOG

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<a href="http://swog.org/Visitors/Download/Policies/Policy35.pdf">http://swog.org/Visitors/Download/Policies/Policy35.pdf</a>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.